StreetInsider.com News Articles

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Wed, 26 Aug 2026 23:58:00 -0400

SHANGHAI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2026 interim financial results and provided corporate updates.

FINANCIAL HIGHLIGHTS

As of June 30, 2026, the company’s total revenue was approximately RMB1,696 million for the first half of 2026 (2026H1), a 45% increase compared to 2025, which was made possible by the rise in sales revenue of pharmaceutical products. In particular, the domestic sales revenue of our core product,

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Wed, 26 Aug 2026 23:58:00 -0400

FINANCIAL HIGHLIGHTS

As of June 30, 2026, the company’s total revenue was approximately RMB1,696 million for the first half of 2026 (2026H1), a 45% increase compared to 2025, which was made possible by the rise in sales revenue of pharmaceutical products. In particular, the domestic sales revenue of our core product,

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Wed, 26 Aug 2026 23:58:00 -0400

FINANCIAL HIGHLIGHTS

As of June 30, 2026, the company’s total revenue was approximately RMB1,696 million for the first half of 2026 (2026H1), a 45% increase compared to 2025, which was made possible by the rise in sales revenue of pharmaceutical products. In particular, the domestic sales revenue of our core product,

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Wed, 26 Aug 2026 23:58:00 -0400

FINANCIAL HIGHLIGHTS

As of June 30, 2026, the company’s total revenue was approximately RMB1,696 million for the first half of 2026 (2026H1), a 45% increase compared to 2025, which was made possible by the rise in sales revenue of pharmaceutical products. In particular, the domestic sales revenue of our core product,

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Wed, 26 Aug 2026 23:58:00 -0400

FINANCIAL HIGHLIGHTS

As of June 30, 2026, the company’s total revenue was approximately RMB1,696 million for the first half of 2026 (2026H1), a 45% increase compared to 2025, which was made possible by the rise in sales revenue of pharmaceutical products. In particular, the domestic sales revenue of our core product,

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Wed, 26 Aug 2026 23:58:00 -0400

FINANCIAL HIGHLIGHTS

As of June 30, 2026, the company’s total revenue was approximately RMB1,696 million for the first half of 2026 (2026H1), a 45% increase compared to 2025, which was made possible by the rise in sales revenue of pharmaceutical products. In particular, the domestic sales revenue of our core product,

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Wed, 26 Aug 2026 23:58:00 -0400

FINANCIAL HIGHLIGHTS

As of June 30, 2026, the company’s total revenue was approximately RMB1,696 million for the first half of 2026 (2026H1), a 45% increase compared to 2025, which was made possible by the rise in sales revenue of pharmaceutical products. In particular, the domestic sales revenue of our core product,

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Wed, 26 Aug 2026 23:58:00 -0400

FINANCIAL HIGHLIGHTS

As of June 30, 2026, the company’s total revenue was approximately RMB1,696 million for the first half of 2026 (2026H1), a 45% increase compared to 2025, which was made possible by the rise in sales revenue of pharmaceutical products. In particular, the domestic sales revenue of our core product,

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Wed, 26 Aug 2026 23:58:00 -0400

FINANCIAL HIGHLIGHTS

As of June 30, 2026, the company’s total revenue was approximately RMB1,696 million for the first half of 2026 (2026H1), a 45% increase compared to 2025, which was made possible by the rise in sales revenue of pharmaceutical products. In particular, the domestic sales revenue of our core product,

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Wed, 26 Aug 2026 23:58:00 -0400

FINANCIAL HIGHLIGHTS

As of June 30, 2026, the company’s total revenue was approximately RMB1,696 million for the first half of 2026 (2026H1), a 45% increase compared to 2025, which was made possible by the rise in sales revenue of pharmaceutical products. In particular, the domestic sales revenue of our core product,

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Wed, 26 Aug 2026 23:58:00 -0400

FINANCIAL HIGHLIGHTS

As of June 30, 2026, the company’s total revenue was approximately RMB1,696 million for the first half of 2026 (2026H1), a 45% increase compared to 2025, which was made possible by the rise in sales revenue of pharmaceutical products. In particular, the domestic sales revenue of our core product,

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Wed, 26 Aug 2026 23:58:00 -0400

FINANCIAL HIGHLIGHTS

As of June 30, 2026, the company’s total revenue was approximately RMB1,696 million for the first half of 2026 (2026H1), a 45% increase compared to 2025, which was made possible by the rise in sales revenue of pharmaceutical products. In particular, the domestic sales revenue of our core product,

Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC